Literature DB >> 11057777

Observations on EGFR gene amplification and polymorphism in prostatic diseases.

V L Kumar1, P K Majumder, V Kumar.   

Abstract

This study was designed to determine the amplification and polymorphism of epidermal growth factor receptor (EGFR) gene in prostatic diseases like benign hypertrophy (BPH) and carcinoma (CaP). The EGFR gene was found to be amplified in grade IV BPH as compared to grade II BPH. Digestion of genomic DNA with MspI and HpaII revealed the presence of a 5kb band following southern blot analysis. This 5kb band was present in all the CaP cases and in one out of three BPH cases. It is possible that such a polymorphism is associated with the type or extent of tumor progression.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11057777     DOI： 10.1023/a:1007160202229

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.266


  8 in total

Review 1.  Receptors for epidermal growth factor and other polypeptide mitogens.

Authors:  G Carpenter
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

2.  Abnormal methylation of estrogen receptor gene and reduced estrogen receptor RNA levels in human endometrial carcinomas.

Authors:  R Piva; V L Kumar; S Hanau; A P Rimondi; S Pansini; G Mollica; L del Senno
Journal:  J Steroid Biochem       Date:  1989-01       Impact factor: 4.292

Review 3.  DNA methylation and gene activity.

Authors:  W Doerfler
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.

Authors:  G L Morris; J G Dodd
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

5.  Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate.

Authors:  V L Kumar; P K Majumder; S Gujral; V Kumar
Journal:  Cancer Lett       Date:  1998-12-25       Impact factor: 8.679

6.  Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines.

Authors:  K Z Ching; E Ramsey; N Pettigrew; R D'Cunha; M Jason; J G Dodd
Journal:  Mol Cell Biochem       Date:  1993-09-22       Impact factor: 3.396

7.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

8.  Cloning of estrogen-regulated messenger ribonucleic acids from rat uterus.

Authors:  C Y Hsu; B S Komm; C R Lyttle; F Frankel
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736
  8 in total
  4 in total

1.  The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.

Authors:  Carmen A Perez; Heidi Chen; Yu Shyr; Regina Courtney; Wei Zheng; Qiuyin Cai; Misun Hwang; Jerry Jaboin; Stephen Schleicher; Luigi Moretti; Marcia Wills; Joseph A Smith; Bo Lu
Journal:  J Urol       Date:  2010-03-19       Impact factor: 7.450

2.  EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.

Authors:  Magdalena M Grabowska; Brindar Sandhu; Mark L Day
Journal:  Cell Signal       Date:  2011-10-14       Impact factor: 4.315

3.  Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Authors:  Bin-Wen Wu; Yuan Wu; Jia-Long Wang; Ju-Sheng Lin; Shu-Yu Yuan; Ai Li; Wu-Ren Cui
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145.

Authors:  Raik Schneider; Günther Gademann; Hans-Joachim Ochel; Karsten Neumann; Burkhard Jandrig; Peter Hass; Mathias Walke; Martin Schostak; Thomas Brunner; Frank Christoph
Journal:  Radiat Oncol       Date:  2021-07-28       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.